Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes

“…Furthermore, the greatest increase in total cholesterol was with licogliflozin 150 mg qd, driven by a significant increase in HDL cholesterol and LDL cholesterol. These findings are consistent with previous reports following SGLT2 inhibition .…”

“…The overall incidence of AEs was lower across groups in this study compared with previous studies (11-23); the reason for this observation, which has been seen with other AHAs (41,42), is not known but may be related to the characteristics of the study population. The pattern of specific AEs observed with CANA in this study was consistent with previous reports (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23), with a higher incidence of AEs related to the mechanism of SGLT2 inhibition (e.g., genital mycotic infections, volume depletion-related AEs, osmotic diuresis-related AEs) observed in all CANA treatment arms versus MET. No differences in gastrointestinal-related AEs were observed with combination therapy compared with MET monotherapy.…”

“…Thus, it seems unlikely that the addition of canagliflozin to the background of a sulfonylurea alone would diminish the extent of weight loss and suggests that the modest reduction in body weight with canagliflozin 100 mg in this study is likely an outlying estimate. Changes in BP, while not significant, were in a similar direction to those observed in other reports [ 5 – 17 ]. Effects on lipid metabolism were also inconsistent and nonsignificant, but the overall pattern appeared to be similar to that reported previously in larger, better powered studies with small increases in LDL-C [ 5 – 17 ].…”

“…Changes in BP, while not significant, were in a similar direction to those observed in other reports [ 5 – 17 ]. Effects on lipid metabolism were also inconsistent and nonsignificant, but the overall pattern appeared to be similar to that reported previously in larger, better powered studies with small increases in LDL-C [ 5 – 17 ]. Importantly, there was no change in the LDL-C/HDL-C ratio with either canagliflozin 300 or 100 mg.…”